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ABSTRACT
TLS (translocated in liposarcoma), also known as
FUS (fused in sarcoma), is an RNA/DNA-binding
protein that plays regulatory roles in transcription,
pre-mRNA splicing and mRNA transport. Mutations
in TLS are responsible for familial amyotrophic
lateral sclerosis (ALS) type 6. Furthermore,
TLS-containing intracellular inclusions are found in
polyglutamine diseases, sporadic ALS, non-SOD1
familial ALS and a subset of frontotemporal lobar
degeneration, indicating a pathological significance
of TLS in a wide variety of neurodegenerative
diseases. Here, we identified TLS domains that de-
termine intracellular localization of the murine TLS.
Among them, PY-NLS located in the C-terminus is a
strong determinant of intracellular localization as
well as splicing regulation of an E1A-derived
minigene. Disruption of PY-NLS promoted the for-
mation of cytoplasmic granules that were partially
overlapped with stress granules and P-bodies.
Some of the ALS-linked mutations altered both
intracellular localization and splicing regulation of
TLS, while most mutations alone did not affect
splicing regulation. However, phospho-mimetic
substitution of Ser505 (or Ser513 in human) could
enhance the effects of ALS mutations, highlight-
ing interplay between post-translational modifica-
tion and ALS-linked mutations. These results
demonstrate that ALS-linked mutations can
variably cause loss of nuclear functions of TLS
depending on the degree of impairment in nuclear
localization.
INTRODUCTION
TLS (translocated in liposarcoma)/FUS (fused in
sarcoma) is an RNA/DNA-binding protein implicated in
multiple diseases. As its name indicates, chromosomal
translocation of TLS was found in sarcoma and
leukemia and results in the production of an oncogenic
fusion protein that consists of the N-terminal portion of
TLS and a partner protein such as CHOP and ERG (1–3).
The N-terminus region of TLS is rich in Gln, Ser, Tyr and
Gly residues (QSYG) and acts as a transcriptional
co-activation domain (4). Recently, TLS has been
implicated in neurodegenerative disorders. Huntington’s
disease (HD) is an autosomal dominant disease caused
by an expansion of a CAG repeat that encodes a
polyglutamine tract in the huntingtin protein. We previ-
ously reported that TLS is a protein component of inclu-
sion bodies in HD patients and a model mouse (5).
Moreover, TLS is also found in the inclusion bodies of
other polyglutamine diseases such as spinocerebellar
ataxia (SCA) type 1, 2 and 3 and dentatorubral-
pallidoluysian atrophy (DRPLA) (6,7). These results
raised a possibility that TLS function is compromised by
polyglutamine disease proteins.
More recently, mutations of TLS were identiﬁed in
familial amyotrophic lateral sclerosis (ALS) type 6
(ALS6) and some sporadic ALS patients (8–10). The in-
heritance of ALS6 is autosomal dominant with the excep-
tion of a recessive mutation, H517Q (8–10). The majority
of mutations have been identiﬁed in exon 15 that encodes
the C-terminal end of the protein, where a nuclear local-
ization signal (NLS) is predicted (10,11). Most others are
missense mutations located in distinct regions of the open
reading frame (10). In ALS6 patients, ubiquitin-positive
cytoplasmic inclusions of TLS have been identiﬁed (8,9).
Furthermore, TLS pathology has been identiﬁed in a
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now classiﬁed as FTLD-FUS, which includes atypical
FTLD with ubiquitinated inclusions (aFTLD-U),
neuronal intermediate ﬁlament inclusion disease
(NIFID) and basophilic inclusion body disease (BIBD)
(6,12–15). These observations indicate that TLS pathology
is common to a wide spectrum of brain diseases.
Remarkably, this situation was preceded by another
RNA-binding protein, TDP-43 (transactive response
DNA-binding protein 43) (10). TDP-43 has been identiﬁed
as a major component of inclusions in sporadic ALS as
well as the majority of FTLD with ubiquitin-positive in-
clusions (FTLD-U) (16). Subsequently, TDP-43 muta-
tions have been found in ALS and FTLD patients
(17,18). TDP-43-positive inclusions were observed in
FTLD caused by mutations of other genes such as GRN
and VCP (16,19). Thus, FTLD subtypes with
TDP-43-positive inclusions are now categorized as
FTLD-TDP (15). Initially, pathological changes of
TDP-43 and TLS were thought to be mutually exclusive,
and TLS was not expected to be present in the inclusions
of FTLD-TDP and most of sporadic ALS (6,10). More
recently, however, TLS immunoreactivity was detected in
TDP-positive inclusions of sporadic ALS, non-SOD1
familial ALS and FTLD with or without GRN mutations
(20). Therefore, TLS and TDP-43 are major proteins ab-
errantly accumulated in a wide range of ALS and FTLD
tissues, suggesting common pathogenic pathways between
these diseases.
In this context, it is crucial to understand the cause and
consequence of TLS mislocalization in the inclusions. It is
still unclear whether ALS6 mutations result in a loss or
gain of function. TLS regulates various steps of RNA me-
tabolisms including transcription, pre-mRNA splicing and
mRNA transport (10). TLS contains three types of
RNA-binding motifs, three Arg–Gly–Gly (RGG) boxes
(RGG1, RGG2 and RGG3), an RNA recognition motif
(RRM), and a zinc-ﬁnger motif (ZnF). The ZnF is
involved in the binding to RNA containing a GGUG
motif, a preferential sequence for TLS (21,22). To date,
two independent TLS knockout mouse strains were estab-
lished (23,24). These models revealed that TLS deﬁciency
causes postnatal lethality in inbred animals, abnormal
neuronal morphology, chromosomal instability, sensitiv-
ity to ionizing irradiation and male infertility (23–25).
However, although an extensive analysis of neurological
or behavioral features has not been conducted, heterozy-
gous animals are healthy. Like TLS, TDP-43 is involved in
transcription and alternative splicing (26,27). TDP-43 is a
nuclear protein and cytoplasmic accumulation of TDP-43
in ALS and FTLD-TDP is accompanied by concomitant
depletion of this protein from the nucleus (16), suggesting
loss of nuclear functions of TDP-43 in these conditions.
Importantly, splicing misregulation of a large number of
genes has been reported in sporadic ALS (28). Considering
the pathological and functional similarity between TLS
and TDP-43 and their common roles in alternative
splicing, it is crucial to characterize splicing regulation of
TLS. Although few splicing targets of TLS have been
identiﬁed (29), the adenoviral E1A minigene has been
shown to be a suitable reporter system to study TLS
splicing regulatory activity (30–32).
Here we tried to identify factors that determine TLS
splicing regulatory activity and its intracellular localiza-
tion. For this purpose, we established a splicing reporter
modiﬁed from E1A, which facilitated the functional
analysis of TLS. We then examined the effect of
ALS-related mutations on the function of TLS and
found deﬁcit of splicing regulation in a subset of ALS
mutants. We also noticed that post-translational protein
modiﬁcations can modulate the function of TLS in com-
bination with ALS mutations.
MATERIALS AND METHODS
cDNA clones and constructs
Murine TLS cDNA fragment was ampliﬁed by polymer-
ase chain reaction (PCR) from TLS-V5 (5) using a primer
pair of BamHI-Tls-Fw and XhoI-Tls-Rv for EGFP-
TLS-ext or BamHI-Tls-Fw and XhoI-Tls-stop-Rv for
EGFP-TLS and inserted in the BglII-SalI sites of
pEGFP-C1 (Clontech). TLS-EGFP was made by inserting
the TLS fragment ampliﬁed by using BamHI-Tls-Fw and
XhoI-Tls-Rv into the BglII-SalI sites of pEGFP-N3
(Clontech). Deletions of TLS were made by PCR.
TLS-M9 fragment was ampliﬁed using BamHI-Tls-Fw
and XhoI-Tls-M9-Rv and inserted in the BglII-SalI sites
of pEGFP-C1. E1A minigene fragment was ampliﬁed
from pCS-MT-E1A, a kind gift from Dr. Moreau-
Gachelin (30), by PCR using a primer set of
BglII-E1A-Fw and SalI-E1A-Rv. This fragment was
inserted in pEGFP-C1 to make EGFP-E1A minigene.
E1A/mut12s and E1A/mut13s were made by introducing
substitutions of 30-splice site of 12s and 13s in the context
of EGFP-E1A. RFP-fused huntingtin exon 1 constructs
(18Qex1-RFP and 108Qex1-RFP) were made by inserting
huntingtin fragments cleaved by HindIII and BamHI from
pcDNA3.1-tNhtt-17Q-EGFP-NLS or pcDNA3.1-tNhtt-
153Q-EGFP-NLS (5) to the HindIII-BamHI sites of
pcDNA3 with RFP (33). Due to the instability of CAG
repeat, the repeat length of mutant huntingtin fragment
was variable. We chose a clone with CAG108 or CAG105
for a mutant fragment. For making NLS-fused constructs,
oligonucleotides encoding SV40 NLS (BamHI-NLS-
BglII-Fw and BamHI-NLS-BglII-Rv) were annealed and
ligated with each other to multimerize NLS and cleaved
with BglII and BamHI to eliminate head-to-head ligation
products. A ladder of multimerized NLS was resolved by
agarose gel electrophoresis and the band corresponding to
three copies of NLS was collected. Recovered DNA from
the band was inserted into the BamHI site of pcDNA3
with RFP to make pcDNA3/NLS-RFP, the BglII site of
pEGFP-C1 to make pEGFP-C1-NLS, or the BamHI site
of pEGFP-N3 to make pEGFP-N3-NLS. 18Qex1-NLS-
RFP and 108Qex1-NLS-RFP were made by inserting
above huntingtin fragments into the HindIII-BamHI
sites of pcDNA3/NLS-RFP. For making EGFP-fused
huntingtin constructs, huntingtin fragment were ampliﬁed
using BamHI-Htt-Fw and XhoI-Htt-Rv from 18Qex1-
RFP and 108Qex1-RFP, and cleaved by BamHI and
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BglII-SalI sites of pEGFP-N3-NLS to make 18Qex1-
NLS-EGFP and 105Qex1-NLS-EGFP, or into the
BglII-SalI sites of pEGFP-N3 to make 18Qex1-EGFP
and 105Qex1-EGFP. G3bp1 and TIAR were ampliﬁed
from mouse cDNA library. A FANTOM3 clone,
G730049H03, encoding Nucleolin (Ncl) was provided
from Dr Hayashizaki (34). cDNA fragments of G3bp1,
TIAR and Ncl were inserted into the BglII-SalI sites of
pEGFP-C1 or pRFP-C1 (35).
RFP-M9M and RFP-Bimax2 were made by inserting
annealed oligonucleotides encoding M9M and Bimax2
into the BglII-SalI site of pRFP-C1. For making
NES-TLS, NES-encoding oligonucleotides, BspEI-NES-
Fw and BglII-NES-Rv, were annealed and inserted into
the BspEI-BglII sites of pEGFP-C1 and then TLS was
inserted in the BglII-SalI sites. The sequence of oligo-
nucleotides is shown in Supplementary Table S1. All con-
structs were conﬁrmed by sequencing.
Antibodies and reagents
Mouse anti-myc and Alexa-conjugated secondary
antibodies were from Invitrogen; rabbit anti-GFP (598)
and rabbit anti-Rck/p54/DDX6 (PD009) were from
MBL; mouse anti-CUGBP1 (3B1), goat anti-LaminB
(M-20), goat anti-eIF3B (sc-16377), goat anti-TIAR
(C-18, sc-1749) and rabbit anti-eIF2a (FL-315, sc-11386)
were from Santa Cruz Biotechnology; rabbit anti-FUS
(A300–302A) was from Bethyl Laboratories; mouse
anti-G3bp1 (611126) and mouse anti-TLS (611384) were
from BD Transduction Laboratories; rabbit anti-FUS
(HPA008784) and rabbit anti-Nucleolin (N2662) were
from Sigma-Aldrich; rabbit anti-eIF4G (#2498) was
from Cell Signaling Technology. Rabbit anti-TLS-M
and anti-TLS-C were described previously (5). Emetine
and leptomycin B were purchased from Sigma-Aldrich.
Puromycin, G418 and blasticidin were from Invitrogen.
Actinomycin D was from Nacalai Tesque.
Cell culture and transfection
N2a, COS-7 and HeLa cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum. For minigene
assays, cells were cultured in 12-well plates and trans-
fected with 0.5mg of plasmids for protein expression
and 0.01mg of plasmids for the expression of a minigene
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. For western blot and im-
munocytochemistry, see Supplementary Materials and
Methods.
Cellular splicing assay
Transfection and cDNA synthesis from cellular RNA
were performed as previously described (35).
Transfection efﬁciency was equivalent among constructs
in N2a cells, which was determined by the fraction of
EGFP-positive cells ( 80%). Minigene fragments were
ampliﬁed by PCR using a ﬂuorescein isothiocyanate
(FITC)-labeled forward primer, FITC-E1A-splicing-ex1-
Fw and a non-labeled reverse primer, E1A-splicing-ex2-
Rv. For E1A/mut12s and E1A/mut13s minigenes,
FITC-GFP-Fw and E1A-splicing-ex2-Rv were used for
ampliﬁcation. The sequence of primers is listed in
Supplementary Table S1. PCR products were resolved
by 2.5% agarose gel electrophoresis. The ﬂuorescence of
PCR products was captured by LAS1000 (FUJIFILM).
Intensity of band signals was quantiﬁed by Multigauge
software (FUJIFILM). For the quantiﬁcation of E1A/
mut12s splicing, the ratio of 9s was calculated as 9s/
(9s+13s) 100.
Determination of nucleocytoplasmic localization of
EGFP-tagged proteins
EGFP-tagged constructs were transfected into N2a or
COS-7 cells plated in 24-well plastic plates. Twenty-four
hours post-transfection, cells were ﬁxed with 4%
paraformaldehyde/PBS containing Hoechst 33342 for
30min and washed three times with PBS. ArrayScanV
TI
High Content Screening Reader (Cellomics) was utilized
for ﬂuorescent cell image analysis. Cells were identiﬁed by
their nucleus stained by Hoechst and EGFP-positive cells
were selected. For each EGFP-positive cell, average
EGFP intensities inside and outside of the nucleus were
quantiﬁed. A nucleocytoplasmic index (NCI) was deﬁned
as (cytoplasmic intensity per pixel)/(cytoplasmic intensity
per pixel+nuclear intensity per pixel). This value ranges
from 0 to 1 and a higher value indicates stronger cyto-
plasmic localization in the cell. In one experiment, at least
150 cells were analyzed for each construct and the
average NCI value of the cell population was calculated.
The ‘average NCI’ value shown in the ﬁgures are the
mean of average NCI determined from at least three rep-
licates. When necessary, cells were treated with




We ﬁrst examined the distribution of endogenous TLS in
mouse tissues. TLS was detected predominantly in the
nuclei of cells in the cerebral cortex, spinal cord and
striatum using multiple antibodies recognizing different
regions of the protein (Figure 1A for anti-TLS-C and
data not shown). Similarly, intracellular localization of
endogenous TLS in mouse neuroblastoma Neuro2a
(N2a) cells was detected exclusively in the nucleus using
anti-TLS antibodies (Figure 1B and data not shown). We
utilized murine TLS that was fused to enhanced green
ﬂuorescent protein (EGFP) at the N-terminus of TLS
(EGFP-TLS). EGFP-TLS localized in the nucleus in
N2a cells, as with the endogenous TLS (Figure 1B). In
contrast, when EGFP was fused at the C-terminus of
TLS (TLS-EGFP), the resultant protein was localized in
both nucleus and cytoplasm with occasional formation of
cytoplasmic inclusion-like structures or granules
(Supplementary Figure S1A and B). Similar intracellular
localization was observed when EGFP was fused to the
N-terminus of TLS lacking its own stop codon and an
Nucleic Acids Research,2011, Vol.39, No. 7 2783extension of l3 amino acids derived from the vector was
located at the C-terminus (EGFP-TLS-ext;
Supplementary Figure S1A and C). These results sug-
gested that tagging at the C-terminus of TLS can affect
its subcellular localization. We next examined the splicing
regulatory activity of EGFP-TLS. We utilized the E1A
minigene (Figure 1C), a known splicing substrate
regulated by TLS (30,32). EGFP-TLS increased the ratio
of the shortest spliced product, 9s and decreased both 13s
and 12s, consistently with the previous results (32).
Finally, as in the case of endogenous TLS (5),
EGFP-TLS was sequestered by the inclusion bodies of
mutant huntingtin exon 1 fused with monomeric red
ﬂuorescent protein (RFP) (Figure 1D). Similarly,
RFP-fused TLS localized in the nucleus as with
EGFP-TLS and was sequestered by aggregates of
mutant huntingtin exon1 (Supplementary Figure S1D).
Thus, EGFP-TLS reproduced previously known
features. Based on these results, we decided to use
EGFP-TLS as a model protein in the subsequent studies.
Determinants of TLS regions for intracellular localization
We examined a number of deletion mutants of
EGFP-TLS to identify the determinants of intracellular
localization (Figure 2 and Supplementary Figure S2).
Figure 1. Characterization of EGFP-TLS as a model protein. (A) Immunohistochemical analysis of endogenous TLS cerebral cortex, spinal cord and
striatum of mouse at the age of 16 weeks. Sections were stained using anti-TLS-C polyclonal antibody. Scale bar represents 20mm. (B) Intracellular
localization of endogenous and recombinant TLS in N2A cells. Endogenous TLS was immunostained with a polyclonal antibody against a
C-terminal region of TLS and detected by the ﬂuorescence of Alexa 488 conjugated to the secondary antibody (upper panels). EGFP-TLS was
transfected into N2a cells and detected by the ﬂuorescence of EGFP (lower panels). Images were obtained by confocal ﬂuorescence microscopy.
Hoechst33342 was used for staining the nucleus. (C) Structures of the E1A minigene (top left). Spliced and unspliced products are depicted. Splicing
assay of E1A minigene of N2a cell transfected with either EGFP or EGFP-TLS (top right). Bottom, quantiﬁed results of E1A splicing assay. Bars
represent spliced or unspliced products (mean±SD, n=3). (D) Sequestration of EGFP-TLS by huntingtin exon 1 containing 108Q fused with NLS
and RFP. Confocal ﬂuorescent images of EGFP and RFP are shown together with nuclear staining with Hoechst 33342. Scale bars in (B) and (D)
represent 10mm.
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we measured EGFP intensity in both nucleus and cyto-
plasm of transfected cells. Relative contribution of cyto-
plasmic intensity in each cell was represented by a value
designated a nucleocytoplasmic index (NCI). NCI ranges
from 0 to 1 and a higher NCI indicates stronger cytoplas-
mic localization of the cell. An average NCI was
calculated from the NCI values of all transfected cells of
a construct and was used as a simple indicator of localiza-
tion. For example, EGFP showed an average NCI value
around 0.5. The average NCIs of EGFP-nucleolin
(nuclear protein) and EGFP-G3bp1 (cytoplasmic
protein) were 0.1 and 0.9, respectively (Supplementary
Figure S3A).
PY-NLS is a class of NLS that is mediated by
transportin/karyopherin b-2 and can be predicted by con-
sensus motifs (11). Interestingly, a previous study pre-
dicted a PY-NLS at the very C-terminus of TLS, which
directly binds with transportin (11). Consistently, all
mutants containing the C-terminus region (amino acids
500–518) localized exclusively in the nucleus (Figure 2
and Grich-PY, RGG2-PY and ZnF-PY in Figure 3A).
Interestingly, the full length protein showed exclusion
from the nucleoli, whereas other deletions containing the
PY-NLS region did not show such exclusion (Figure 3A).
This may be determined by the N-terminus QSYG region,
as QSYG exhibited nucleoplasmic distribution with nucle-
olar exclusion similar to the full-length protein, although
QSYG was also localized in the cytoplasm (Figure 3A and
Supplementary Figure S4A). Next, when a C-terminal
region corresponding to exon 15 was deleted, the
protein, ex15, showed enhanced cytoplasmic distribu-
tion (Figures 2 and 3B, top panels). Cells with higher ex-
pression of ex15 tended to exhibit small and/or large
granular structures (Figure 3B, middle and bottom
panels). Thus, PY-NLS promotes nuclear localization
and its disruption leads to cytoplasmic accumulation of
TLS. Similar cytoplasmic structures were observed in the
Figure 2. Summary of intracellular localization of EGFP-TLS deletion mutants. Structure and intracellular localization of EGFP-TLS deletion
mutants in N2a cells are described. Protein domains of TLS are indicated by colored boxes. Average nucleocytoplasmic index (NCI) values
determined for each mutant are shown in the chart (mean±SD, n=3).
Nucleic Acids Research,2011, Vol.39, No. 7 2785cells expressing TLS-EGFP or EGFP-TLS-ext
(Supplementary Figure S1B and C, middle and bottom
panels).
Sequence analysis of TLS protein using NetNES1.1 (36)
predicted a leucine-rich nuclear export signal (NES) in the
RRM region (Figure 3C). Consistently, EGFP-RRM
distributed preferentially in the cytoplasm (Figures 2 and
3C). Treatment with leptomycin B, an inhibitor of
exportin/CRM1-dependent NES, reduced cytoplasmic ac-
cumulation of RRM (+LMB, Figure 3C). Since the
Figure 3. Characterization of PY-NLS and NES of TLS. (A) Intracellular localization of N-terminally deleted mutants and QSYG in N2a cells (top
and middle panels). Exclusion of EGFP-TLS from the nucleoli immunostained by anti-nucleolin (Ncl) antibody (bottom panels). (B) Examples of
intracellular localization of the ex15 mutant. Cells were immunostained by anti-eIF3 antibody (red). (C) Confocal images of RRM (with or without
leptomycin B treatment), Grich-RRM and Grich-RGG1 fragments. Predicted leucine-rich NES sequences in human and mouse TLS are shown in the
top. The consensus sequence of NES is also shown with essential residues in red. Phi represents hydrophobic amino acids, whereas X represents any
of amino acids. Bar chart shows the effect of leptomycin B (LMB) treated at 20nM for 1h (mean±SD, n=3). *P<0.01 in ANOVA and Tukey’s
test. n.s.: not signiﬁcantly changed. (D) Effect of pathway–speciﬁc inhibition of nuclear import of TLS. Cells were transfected with RFP-M9M and
the localization of endogenous TLS was detected by anti-TLS-C antibody. Arrows indicate cells with higher RFP-M9M expression. Arrowheads
indicate cells with little or no RFP-M9M. Scale bars represent 10mm. Hoechst33342 was used for nuclear staining.
2786 Nucleic Acids Research, 2011,Vol.39, No. 7exclusion of RRM from the nucleus was incomplete, the
NES activity seemed relatively weak. Interestingly,
Grich-RRM did not show cytoplasmic accumulation
despite the presence of RRM (Figures 2 and 3C). Since
Grich-RGG1 lacking RRM was diffusely distributed
throughout the cell and did not promote particular local-
ization (Figure 3C), Grich-RGG1 may negatively
modulate the NES activity in the RRM.
Lastly, to directly examine whether disruption of
PY-NLS is sufﬁcient for cytoplasmic localization and/or
granular formation, we used RFP-fused M9M peptide
that speciﬁcally binds to transportin and inhibits
PY-NLS-mediated nuclear localization (37). Cells with
strong RFP ﬂuorescence showed cytoplasmic localization
of endogenous TLS (Figure 3D, arrows), with some
granular structures. The effect of RFP-M9M seemed to
be dose-dependent as cells with weaker or no RFP ﬂuor-
escence showed normal TLS distribution in the nucleus
(Figure 3D, arrowheads). In contrast, TLS was resistant
to RFP-fused Bimax2 (Supplementary Figure S4B),
an inhibitory peptide against importina/b-dependent
classical NLS (38). A similar observation was found
with EGFP-TLS co-transfected with RFP-M9M
(Supplementary Figure S4C). These results veriﬁed the
function and speciﬁcity of the predicted PY-NLS.
Cytoplasmic granules of TLS have the characteristics of
RNA granules
Previously, TLS was reported to be recruited to stress
granules (SGs) in response to stress (39). SG is a cytoplas-
mic structure thought to act as a triage of mRNA to allow
adaptive translation in stressed conditions (40). Larger
cytoplasmic granules of ex15 were colocalized with
eIF3 (Figure 3B, bottom panels), which serve as a
marker of SGs (41,42). Since the cells were not treated
with stress stimuli, this observation indicated that TLS
can induce or nucleate stress granules when overexpressed
as in the case of TIA-1 and G3BP (40). In contrast, smaller
granular structures were not positive for eIF3
immunoreactivity (Figure 3B, middle panels). In N2a
cells, small granules were predominant structure. Large
eIF3-positive granules were observed in roughly 20% of
cells positive for cytoplasmic granules. We then identiﬁed
the region of TLS essential for cytoplasmic granule for-
mation. Grich-RGG3 and RGG2-RGG3 occasionally
showed large cytoplasmic granular structures positive for
eIF3 (Figure 4A), while shorter constructs did not efﬁ-
ciently form such structures. The ZnF motif was not an
essential region as RGG2-RGG3(ZnF) could form
eIF3-positive granules (Figure 4B, arrows in upper
panels). In addition, RGG2-RGG3(ZnF) showed accu-
mulation in the nucleoli (Figure 4B, lower panels), sug-
gesting that the ZnF may inhibit the nucleolar localization
of RGG regions. Then, we tested a variant of EGFP-TLS
(NES-TLS) in which an NES derived from protein kinase
inhibitor alpha (PKI-a) was inserted to enforce cytoplas-
mic localization without directly disrupting the PY-NLS
sequence. NES-TLS exhibited an increased cytoplasmic
localization as expected and occasionally formed small
and large granules (upper and lower panels, respectively,
in Figure 4C). Thus, cytoplasmic localization, rather than
mutation or deletion of PY-NLS itself, is a determinant of
granule formation. Cytoplasmic granules were also
observed in COS-7 cells. In COS-7 cells, large granules
were more prevalent than in N2a and most of cells with
cytoplasmic granules were also positive for eIF3 granular
staining. In addition to eIF3, other SG markers were
colocalized with large, but not small, cytoplasmic
granules (Supplementary Figure S5 and Supplementary
Data).
SGs are known to be dynamic and their assembly is
dependent on the amount of non-polysomal mRNA
(43). Emetine is a translational inhibitor that stabilizes
polysomes and reduces SGs, whereas puromycin,
another translational inhibitor, destabilizes polysomes
and facilitates SG formation. SG-like structures of
ex15 were reduced by emetine treatment, while
enhanced by puromycin (Supplementary Figure S4D).
Finally, we examined the relationship of TLS and
P-bodies (PBs), another class of RNA granules associated
with mRNA silencing and decay (44). Rck/DDx6 was
used as a marker of PBs. Interestingly, some of the
small granules of TLSex15 showed a partial overlap
with PBs (Figure 4D, arrows), whereas other small
granules were independent of PBs in N2a cells
(Figure 4D, arrowheads). eIF3 showed a diffuse distribu-
tion and was not enriched in these TLS small granules
(Figure 4D). Remarkably, cells with highly accumulated
cytoplasmic TLSex15 ( 10% of transfected cells)
showed only a very small number of PBs (Figure 4E,
emphasized by a dashed line in the left bottom panel).
This was observed in most cells with eIF3-positive large
granules and a fraction of cells with small granules. Such
depletion was not observed in cells with high expression of
EGFP or EGFP-TLS (data not shown). In COS-7 cells,
PBs were often preserved in cells with SG-like large
granules (Figure 4F). In these cells, some PBs were
located inside of large TLS granules, a pattern not
observed in N2a cells (Figure 4Fa). Other PBs were
closely located with TLS granules (arrow), or independ-
ently distributed in the cell (arrowhead, Figure 4Fb).
Depletion of PB could be observed in COS-7 cells,
although depletion was less clear than in N2a cells (data
not shown). Thus, despite some cell-speciﬁc differences,
TLS granules are associated with two classes of RNA
granules, SGs and PBs. In addition, the appearance of
PBs was affected by the overload of cytoplasmic TLS.
E1A minigene variants that facilitate the analysis of
splicing regulation
Although the E1A minigene was useful for splicing
analysis of TLS, the interpretation of the results was
complicated by the multiplicity of splice products. To
simplify the analysis of E1A splicing, we tested two
variants of E1A that were designed to disrupt one of
major spliced isoforms (12s or 13s) by mutating the
ﬂanking spliced site (Figure 5A). As expected, both
E1A/mut13s and E1A/mut12s minigenes did not show
the spliced product corresponding to 13s and 12s, respect-
ively (Figure 5B). When EGFP-TLS was transfected, an
Nucleic Acids Research,2011, Vol.39, No. 7 2787increase in 9s was observed with both minigenes
(Figure 5B). Therefore, the responsiveness of E1A to
EGFP-TLS was retained in these variant minigenes.
Since these minigene showed only two major spliced
products (9s and either 12s or 13s), these could simplify
the splicing analysis. We used the E1A/mut12s minigene
for the subsequent studies.
Determinants of TLS splicing activity
We tested TLS deletion mutants in an E1A/mut12s
splicing assay to identify TLS domains contributing to
splicing regulation. As shown in Figure 5C, deletion of
QSYG and Grich-RRG1 and RRM regions did not
impair the activity of EGFP-TLS. We then tested
Figure 4. Cytoplasmic localization of TLS. (A) Grich-RGG3 and RGG2-RGG3 are sufﬁcient for formation of SG-like large granular structures.
N2a cells were immunostained by anti-eIF3 antibody. (B) Top panels show the intracellular localization of RGG2-RGG3ZnF. The ZnF motif is
dispensable for formation of SG-like granules (arrows). Bottom panels show the accumulation of RGG2-RGG3ZnF in the nucleolus. Nucleoli were
detected by anti-Ncl antibody. (C) Cytoplasmic accumulation of NES-TLS. Small (top panels) or large (bottom panels) granules were observed.
Large granules were positive for anti-eIF3. (D) Partial overlap of TLSex15 small granules with PBs in N2a cells. Transfected cells were
immunostained with anti-Rck (red) and anti-eIF3 (blue). Right panels are magniﬁed images of the boxed region in the left panels. Arrows
indicate TLS small granules overlapped with PBs. Arrowheads indicate TLS small granules not overlapped with PBs. eIF3 was not enriched in
TLS small granules. Scale bars represent 10mm. (E) PBs are depleted in N2a cells with higher accumulation of ex15. PBs were immunostained by
anti-Rck. Bottom left panel is identical to top right panel with an exception that the shape of the cell with strong expression of ex15 is emphasized
by a dashed line. Flanking cells without ex15 ﬂuorescence contain PBs. (F) Interaction between large granules of ex15 and P-bodies. Cells were
immunostained with anti-Rck antibody to visualize PBs in COS-7 cells. Magniﬁed images of indicated regions are also shown (a and b). Scale bars
represent 10mm.
2788 Nucleic Acids Research, 2011,Vol.39, No. 7further deletions from RGG2-PY to specify the essential
domains. Deletion of any of RGG2, ZnF, or PY-NLS
weakened the regulatory activity (Figure 5C). Thus, a
C-terminal region from RGG2 to PY-NLS is the
minimal region for an optimal splicing regulatory
activity. We also tested internal deletions of
Grich-RGG1, RRM, RGG2 or RGG3. Deletion of
RGG2, but not the other regions, reduced the activity of
EGFP-TLS (Figure 5D). Although the level of protein
expression was variable among constructs, this could not
explain the difference of splicing activity because all
proteins showed protein expression equivalent to or
higher than TLS (Supplementary Figure S6A and B). In
conclusion, two RNA-binding motifs, ZnF and RGG2
Figure 5. Splicing assay of EGFP-TLS using a variant of the E1A minigene. (A) Structure of variant minigenes of E1A. Mut13s and mut12s were
made by substation of E1A minigene at the 50-splice site of 13s and 12s, respectively. (B) RT–PCR results of splicing assay using E1A/mut13s and
E1A/mut12s in N2a cells. Minigenes were transfected with either EGFP or EGFP-TLS. (C) Comparative analysis of TLS deletion mutants using
E1A/mut12s. Structures of mutants are shown in the left. Representative gel image of RT–PCR is shown. Bars represent the ratio of the 9s spliced
product (mean±SD, n=4–7). (D) Splicing regulation of TLS internal deletion mutants. The structure of mutants is shown in the left. Bar chart
shows the results of splicing assay as in (C)( n=3–7). *P<0.05, ANOVA and Dunnett’s test in comparison with EGFP.
Nucleic Acids Research,2011, Vol.39, No. 7 2789and the PY-NLS are essential for the splicing regulation
by TLS.
Although the contribution of PY-NLS to the splicing
regulation was reasonable, it was not excluded that the
C-terminal region overlapped with another functional
motif involved in the splicing regulation. We examined a
mutant of TLS (TLS-M9) in which the PY-NLS of TLS
was substituted by that of hnRNP A1, known as M9NLS
(Supplementary Figure S7A). This substitution changed
most residues in the C-terminal region. TLS-M9 was in-
distinguishable from TLS in both subcellular localization
and splicing regulation (Supplementary Figure S7B and
C). Thus, the role of the C-terminal region in the
splicing regulation was sufﬁciently explained by the
nuclear localization activity of PY-NLS.
The effect of ALS-associated mutations on intracellular
localization
We next examined the effect of ALS-linked mutations on
murine TLS activity and localization (Figure 6A). We ﬁrst
tested the intracellular localization of TLS mutants in N2a
cells (Figure 6B and Supplementary Figure S8).
Remarkably, K502E, R514G and P517L showed strong
cytoplasmic localization (Figure 6B and red bars in C).
All these residues were included in the consensus
residues of PY-NLS (residues in red in Figure 6A) that
was predicted previously (11). Other mutations were not
signiﬁcantly different from wild-type TLS except for a
small increase in average NCI of R506G (Figure 6C).
However, a detailed analysis of NCI distribution
revealed that H509P, R510K, R513G and R516S
showed a small increase in the fraction of cells with NCI
greater than 0.1 when compared to wild-type TLS
(Supplementary Figure S3B). Interestingly, R506G,
H509P and R513G showed clear increase in average
NCI in COS-7 cells (Supplementary Figure S3C). We
tested several drugs and found that actinomycin D
(ActD), a transcription inhibitor, enhanced cytoplasmic
localization of wild-type TLS in N2a cells (Figure 6C).
Strikingly, however, all C-terminal mutants showed
higher cytoplasmic localization compared to wild-type
TLS in the presence of ActD (Figure 6C, gray bars).
ActD did not alter the localization of EGFP alone (data
not shown). Thus, localization of the C-terminal mutants
was variable and dependent on cell types and cellular con-
ditions. In contrast, N-terminal mutations did not cause
major changes in nucleocytoplasmic distribution of TLS.
Cytoplasmic TLS formed large and small granular
structures as observed for TLSex15 and NES-TLS
(Figure 6D–F and Supplementary Figure S8). For
example, P517L showed cytoplasmic accumulation with
some large granules colocalized with eIF3 (Figure 6D).
Small granules of P517L were occasionally colocalized
with PBs but not with SGs (Figure 6E and
Supplementary Figure S4E). Most notably, cells with a
massive accumulation of P517L had fewer PBs as in the
case of ex15 (Figure 6F). We prepared cells strongly
expressing EGFP-P517L using ﬂuorescence-activated cell
sorting (FACS) to enrich PB-depleted cells. In a western
blot analysis, the level of Rck was not decreased in
P517L-expressing cells compared to corresponding cell
populations of EGFP or EGFP-TLS (Supplementary
Figure S4F), suggesting that the observed loss of PBs by
P517L was likely due to redistribution of Rck rather than
its reduction.
To exclude that EGFP-tag in the N-terminus affected
the localization of TLS, we examined the localization of
tag-free TLS with or without ALS mutations. We utilized
an N2a-derived cell line stably expressing artiﬁcial
microRNA (miRNA) that effectively silenced the en-
dogenous TLS (TLS-KD cells, Supplementary Figure
S9A and B). TLS(res) was designed to be resistant to the
miRNA-mediated RNAi because of substitutions in the
region targeted by the miRNA (Supplementary Figure
S9C). TLS(res) without any tag was transfected into the
TLS-KD cells, which allowed speciﬁc detection of
TLS(res) by anti-TLS antibodies. Subcellular localization
of tag-free TLS(res) and its mutants was consistent with
that of EGFP-fused ones (Supplementary Figure S9D). In
addition, human tag-free TLS with P525L mutation (cor-
responding to P517L in mouse) showed intracellular local-
ization similarly to the mouse counterpart (Supplementary
Figure S9E).
The effect of ALS-linked mutations on E1A splicing
Since some of ALS-linked mutations altered the localiza-
tion of TLS, it was expected that these mutations affect
splicing regulation as well. Although other mutations did
not affect subcellular localization, we thought they could
affect splicing by disrupting protein–RNA or protein–
protein interactions even with normal nuclear localization.
We examined the effect of ALS-linked mutations on the
splicing regulatory activity of EGFP-TLS. Among the
TLS mutants examined, K502E, R514G and P517L ex-
hibited aberrant regulation of E1A/mut12s splicing
(Figure 7A). This was not due to decreased protein expres-
sion of these mutants (Figure 7B). Rather, these mutants
showed a non-signiﬁcant tendency towards increased
protein levels. All the other mutations did not signiﬁcantly
affect splicing regulation (Figure 7A), consistent with their
predominant localization in the nucleus (Figure 6B and
C). Thus, there was a clear correlation between mutations
of PY-NLS consensus sequence (Figure 6A, residues in
red) and deﬁcits in splicing (Figure 7).
Phospho-mimetic substitution at Ser505 modulates the
effects of ALS-linked mutants
As demonstrated in Figure 6, intracellular localization of
TLS mutants could be dependent on the context including
protein environment and/or modiﬁcations. We noticed
that Ser505 (Ser513 in human) located in the PY-NLS
region is a potential phosphorylation site of multiple
kinases including CK2, DNA-PK, GSK3, PKC, PKR
and others, which were predicted by Group-based
Phosphorylation Scoring Method (45). We introduced a
phospho-mimetic mutation of S505D in EGFP-TLS and
some of the mutants. Although S505D itself did not alter
the nucleocytoplasmic distribution of wild-type TLS, this
substitution clearly enhanced cytoplasmic localization of
G499D, H509P, R510K, R513G and R516S in both N2a
2790 Nucleic Acids Research, 2011,Vol.39, No. 7and COS-7 cells (Figure 8A). In contrast, the distribution
of S505D/H509Q was not different from H509Q in these
cells (Figure 8A). Although H509Q and H509P are muta-
tions of the same residue, the effect of S505D on these
mutants were dramatically different (Figure 8A and B).
We also tested splicing regulatory activity of these
mutants. While S505D and S505D/H509Q exhibited
normal splicing regulation of E1A/mut12s, S505D/
H509P and S505D/R510K showed an impaired regulation
with a greater extent for S505D/H509P (Figure 8C).
Figure 6. Intracellular localization of ALS-linked mutants of EGFP-TLS. (A) ALS-linked mutations examined in this study. Mouse TLS mutations
corresponding to known human mutations are indicated. Consensus residues of PY-NLS are shown in red and underlined. Residues encoded by exon
15 are boxed. (B) Intracellular localization of EGFP-TLS harboring above mutations in N2a cells. (C) Bars represent the average NCI (mean±SD,
n=3) of ALS-linked mutants in untreated N2a cells (red bars) or actinomycin D-treated N2a cells (gray bars). *P<0.05 in ANOVA and Dunnett’s
test in comparison with TLS. Red and dark asterisks indicate signiﬁcant difference from TLS in the absence and presence of ActD, respectively.
(D) An example of cytoplasmic granular structures formed by TLS mutants. (E) Partial colocalization of EGFP-P517L and PBs. EGFP-P517L
showed partial colocalization with granules immunoreactive with anti-Rck. (F) Cells with higher expression of EGFP-P517L (arrows) showed a
reduced number of PBs. PBs were immunostained by anti-Rck antibody. Scale bars represent 10mm in (B, D, E and F).
Nucleic Acids Research,2011, Vol.39, No. 7 2791Protein levels of these two mutants were not decreased
compared to others (Supplementary Figure S6C). Thus,
the effect of ALS-linked mutations in the C-terminus
could be enhanced by phosphorylation at S505,
although this effect was dependent on individual
mutations.
DISCUSSION
Identiﬁcation of TLS mutations in ALS raises the
question of whether these mutations result in gain or
loss of function of the protein. TLS mutations were
found in multiple regions in the gene. In addition, TLS
pathology has been identiﬁed in FTLD and ALS patients
even without TLS mutation. These observations empha-
size the importance of understanding the determinants of
the TLS function and localization. Here, we identiﬁed
multiple structural determinants of TLS and provide the
ﬁrst evidence for the effect of ALS-linked mutations on a
nuclear function of TLS.
Determinants of intracellular localization and splicing
regulatory activity of TLS
By an extensive deletion analysis, we have identiﬁed TLS
domains that determine the intracellular properties of TLS
(Figure 9A). First, a previously predicted PY-NLS located
in the C-terminus was veriﬁed by the sensitivity to a
speciﬁc inhibitor, M9M. In addition, the effect of
PY-NLS mutations was stronger when the consensus
residues were mutated (Figure 6C). Since all TLS
deletion mutants containing PY-NLS were always
localized exclusively in the nucleus (Figure 2), PY-NLS
is a dominant determinant of localization. Second, an
NES was predicted and functionally veriﬁed by a speciﬁc
inhibitor, leptomycin B (Figure 3C). Remarkably, the
Grich-RGG1 region was found to suppress cytoplasmic
accumulation of RRM, suggesting a context-dependent
activity of the NES. Third, QSYG in the N-terminus
showed accumulation in the nucleoplasm and exclusion
from the nucleolus. On the other hand, RGG2 and
RGG3 showed a propensity to accumulate in the
nucleoli, which was suppressed by the presence of ZnF.
RGG2 and RGG3 may be involved in the nucleolar local-
ization of TLS upon inhibition of RNA polymerase II
(46). However, in normal state, this effect seems to be
suppressed by ZnF (or perhaps by mRNA-binding) and
antagonized by the QSYG region. Interestingly, TLS was
found to be a component of Drosha-DGCR8 complex
associated with miRNA processing and nucleolar com-
partment (47,48). However, TLS may not be an essential
component of miRNA biogenesis as TLS-KD cells could
maintain miRNA-mediated gene silencing despite a severe
Figure 7. Splicing regulation of ALS-linked mutants of EGFP-TLS. (A) Quantiﬁcation of splicing assay results using E1A/mut12s. Bars represent
the ratio of 9S (mean±SD). All TLS mutants except for K502E, R514G and P517L exhibited statistically signiﬁcant difference from EGFP
(P<0.01), while K502E, R514G and P517L were different from wild-type TLS (*P<0.01, ANOVA and Tukey’s test. n=4–7). (B) The expression
levels of TLS mutants. EGFP-TLS mutants were detected using anti-GFP antibody in a western blot analysis. Bar chart shows the relative protein
levels of wild-type or mutant EGFP-TLS that were normalized by LaminB (mean±SD, n=4). No signiﬁcant difference from the wild-type was
detected by ANOVA and Dunnett’s test. G158E reproducibly showed slightly slower migration compared to the others.
2792 Nucleic Acids Research, 2011,Vol.39, No. 7depletion of TLS (Supplementary Figure S9A). Finally,
RGG2, ZnF and PY-NLS were found to be essential
for splicing regulation of TLS. The former two motifs
may play a role in RNA-binding and the PY-NLS in-
creases the nuclear concentration of TLS, which may
synergistically facilitate splicing regulation. Thus, these
results revealed not only the localization of TLS sub-
regions but also potential interactions among multiple
domains. In this regard, it is interesting that the
N-terminus and C-terminus of TLS binds to each other,
Figure 8. Phospho-mimetic substitution at Ser505 variably enhances the effects of ALS-linked mutations. (A) Intracellular localization of TLS and
its mutants with or without S505D substitution in N2a (top) or COS-7 (bottom) cells. Bars represent average NCI values (mean±SD, n=3). For
each mutant, open and red bars indicate non-substituted S505 and S505D, respectively. *P<0.05 in comparison with S505 in two-tailed t-test.
(B) Intracellular localization of S505D/H509Q (left panels) and S505D/H509P (right panels) in N2a cells. Scale bar indicates 10mm. (C) S505D
substitution modulates splicing regulation of E1A/mut12s in N2a cells. Bars represent the ratio of the 9s spliced product as in Figure 5 (mean±SD,
n=3). TLS, S505D and S505D/H509Q showed signiﬁcantly higher ratio of 9s compared to EGFP (P<0.05). On the other hand, S505D and S505D/
H509Q was not signiﬁcantly different from TLS. In addition, S505D/H509P and S505D/R510K showed signiﬁcantly decreased activity compared to
TLS, with a greater extent for S505D/H509P (**P<0.01 and *P<0.05, ANOVA and Tukey’s test).
Nucleic Acids Research,2011, Vol.39, No. 7 2793and this interaction is allosterically regulated by RNA
(49). In addition, several post-translational modiﬁcations
of TLS have been identiﬁed and some of them can
modulate the intracellular localization or nucleic acid
binding of TLS (50–54). Taken together, complex inter-
actions and regulations among multiple subregions of TLS
through RNA-binding and/or post-translational modiﬁca-
tions might underlie the multifunctional aspects of TLS.
In this study, we utilized EGFP-fused TLS, which faith-
fully reproduced nuclear localization of TLS. In contrast,
TLS-EGFP lost exclusive nuclear localization
(Supplementary Figure S1). This was not simply because
of the size of EGFP as a tag, since a similar effect was
observed with EGFP-TLS-ext containing an extension of
only 13 amino acids (Supplementary Figure S1). It is
unusual that C-terminal extension or tagging affected
the function of PY-NLS, since this motif can be found
in internal regions of other proteins. One possibility is
that the C-terminal residues used in this study
(Supplementary Figure S1) are speciﬁcally incompatible
with the PY-NLS. Alternatively, PY-NLS of TLS might
have to be located at the end of the protein.
Variable effects of ALS-linked mutations
In this study, we utilized the murine TLS protein and its
mutants. This may be suboptimal for understanding TLS
in the context of human disease. However, TLS is a highly
conserved protein and the key molecular features of TLS
are expected to be conserved. In particular, the C-terminus
region is perfectly conserved. In addition, the analysis of
murine protein is directly relevant to the studies using
mouse tissues and genetic models.
Series of experiments clearly demonstrate that PY-NLS
function is tightly correlated with not only nuclear local-
ization but also splicing regulation. The effects of ALS
mutations on splicing could not be attributed to altered
expression level or functional motifs in the C-terminus
other than PY-NLS (Figure 7B and Supplementary
Figure S7). One clear conclusion is that among the muta-
tions in the PY-NLS region, those that alter the consensus
residues of PY-NLS affect both localization and splicing
much more strongly than others. In contrast, the other
mutations in the C-terminus exhibited more variable
effects, which are highly dependent on the context
including cell types, conditions and protein modiﬁcations
(Figures 6C, 8A, B and Supplementary Figure S3C). For
example, we observed little or no difference in both local-
ization and splicing regulation between H509Q and
H509P in N2a cells (Figures 6B, C and 7A). Despite the
mutation of the same residue, H509P showed dramatically
stronger effects on both cytoplasmic localization and
splicing regulation than H509Q when combined with
S505D substitution (Figure 8). This is of interest because
their human counterparts H517Q and H517P are
associated with recessive and dominant inheritance,
Figure 9. Structural determinants of the properties of TLS and the effects of C-terminal ALS-linked mutations. (A) Roles and interplays of TLS
internal domains. The effects of each domain found in this study are depicted. See discussion for detail. (B) Classiﬁcation of C-terminal ALS
mutations. C-terminal mutations could be clearly divided into two groups, PY-NLS consensus mutations and non-consensus mutations. The order of
the effects among mutants was based on Figures 6C, 8A, Supplementary Figure S3B and C. The sequence of the PY-NLS region is shown as in
Figure 6A.
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regulation with the mode of inheritance. Another interest-
ing ﬁnding is that all C-terminal mutants including H509Q
showed an enhanced cytoplasmic localization compared
with wild-type in the presence of ActD (Figure 6C). The
difference of the effects between ActD and S505D (Figures
6C and 8A) suggests that the effect of ActD may involve a
mechanism other than S505 modiﬁcation. Based on the
results of localization and splicing regulation, we classiﬁed
C-terminal mutations as shown in Figure 9B. We specu-
late that the effects of ALS-linked mutations may be
maximized in some cell type(s) of spinal cord depending
on cellular conditions. These results verify that C-terminal
mutations can cause an aspect of loss of nuclear function
of TLS. It is interesting to examine whether splicing
misregulation is observed in ALS6 patients as in
sporadic ALS (28). In addition, other nuclear functions
of TLS such as transcriptional regulation might be also
affected by the disruption of PY-NLS. S505D and
possibly other modiﬁcations may alter the afﬁnity
between PY-NLS and transportin together with
ALS-linked mutations. Currently, some of post-
translational modiﬁcations of TLS were reported to alter
the properties of TLS, though the phosphorylation of
S505 has not been identiﬁed (50–52). Arginine methyla-
tion is of interest as it can promote nuclear exclusion of
EWS, a paralog of TLS (55,56).
We found that non-C-terminal mutations showed no
effects on localization or splicing regulation. Lack of
mislocalization was not due to the EGFP tag in the
N-terminus, since tag-free non-C-terminal mutants were
also localized exclusively in the nucleus (Supplementary
Figure S9D). In addition, S505D did not enhance the
effect of these non-C-terminal mutations (Figure 8A).
Currently, there are some possibilities regarding the
effect of non-C-terminal mutations on TLS function.
The non-C-terminal and C-terminal mutants might cause
some speciﬁc deﬁcits other than splicing regulation.
Alternatively, non-C-terminal mutations might involve a
distinct pathogenic pathway from C-terminal mutations.
In both cases, it is also possible that some
post-translational modiﬁcation other than S505 phosphor-
ylation and/or some speciﬁc cellular condition including
cell types are required for the pathological effects of
non-C-terminal mutations.
Cytoplasmic granules of TLS
Mutations that affect PY-NLS resulted in the formation
of cytoplasmic granules that include SG-like structures.
Although SGs are induced by various stresses as indicated
by the name, more than 10 proteins are known to nucleate
or induce SGs by themselves when overexpressed (40).
Although the physiological and pathological signiﬁcance
of protein-induced SG formation is not well understood,
this may cause not only cytoplasmic sequestration of TLS
but also reorganization of intracellular ribonucleoprotein
complexes and alter mRNA metabolisms. Indeed, the
integrity of PBs was affected in cells with massive cyto-
plasmic accumulation of TLS as determined by the
localization of Rck, an essential component of PBs (57).
Thus, TLS mutants could have an aspect of gain of
function, in which the interactions and ﬂux of
RNA-binding proteins and mRNA are misregulated.
Remarkably, basophilic inclusions found in BIBD
patients are positive for SG markers such as TIA-1 and
PABP and also contain TLS, highlighting the relationship
between TLS inclusions and SGs (14,58). In addition to
SGs, we observed smaller cytoplasmic granules of TLS
partially colocalized with PBs, although many small
granules were negative for both anti-eIF3 and anti-Rck.
It is possible that these small granules are immature SGs
and occasionally fused or docked with existing PBs (59).
For future analyses, these RNA granule-like structures
must be investigated in neurons since TLS is a component
of neuronal granules involved in mRNA transport
(60–62). Such cytoplasmic fraction of TLS with or
without mutations may be predisposed to the assembly
of SGs.
During the article preparation, a paper with closely
related subjects was published (63). In agreement with
our results, nuclear localization of HA-tagged human
TLS in HeLa cells is altered depending on the mutation
in the PY-NLS, while non-C-terminal mutations do not
affect nuclear localization. In addition, ALS-linked muta-
tions facilitate recruitment of TLS into SGs (63).
Although our results are consistent with the report, one
experimental difference is that in their study recruitment
of TLS into SGs required stress treatment. The discrep-
ancy can be because of the cell type utilized. Consistent
with their results, we hardly observed SG-like granules of
our TLS constructs in HeLa cells (data not shown). In
contrast, SG-like granules were easily observed in COS-7
cells, suggesting the importance of the cell type. In this
regard, it is important to note that our P517L construct
could form cytoplasmic granules in primary cortical
neurons (unpublished data). Furthermore, we also tested
tag-free P517L mutant and its human counterpart in N2a
cells and observed cytoplasmic granules (Supplementary
Figure S9D and E). Therefore, the formation of cytoplas-
mic granules is not an artifact of EGFP-tagging and could
be a common feature of human and mouse TLS.
In conclusion, ALS-linked mutations variably disrupt
not only PY-NLS but also splicing regulation and their
effects are enhanced by post-translation modiﬁcations
such as phosphorylation. ALS-linked mutations could be
classiﬁed into three groups, PY-NLS consensus muta-
tions, non-consensus C-terminal mutations and non-C-
terminal mutations. Currently, the effects of non-C-
terminal mutations are unclear. Therefore, an important
next step is to determine the protein modiﬁcation of TLS
and analyze their effects in combination with ALS-linked
mutations. In addition, it is indispensable to characterize
neuropathological and clinical genotype–phenotype cor-
relation in patients with TLS mutations, especially for
non-C-terminal mutations. Lastly, our results emphasize
the importance of understanding the mechanism of RNA
granule metabolisms, as TLS is involved in the regulation
of both SGs and PBs. Remarkably, known SG inducers
include proteins associated with neurological diseases such
as FMRP, SMN1, DISC1, TIA-1, TIAR and angiogenin
(64–69). Cell type-dependent differences in the properties
Nucleic Acids Research,2011, Vol.39, No. 7 2795of RNA granules might be another general issue to be
elucidated.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
The authors would like to thank Drs Moreau-Gachelin
and Hayashizaki for E1A minigene and FANTOM3
clone, respectively, and members of the Laboratory for
Structural Neuropathology for daily help and discussions.
The authors are also thankful to staffs of Research
Resource Center of RIKEN Brain Science Institute for
DNA sequencing and cell sorting.
FUNDING
Grants-in-Aid for Scientiﬁc Research from The Ministry
of Education, Culture, Sports, Science and Technology
(19790620 and 21790854 to Y.K., 22240037 and
22110004 to N.N.); Core Research for Evolutional
Science and Technology from Japan Science and
Technology Agency (to N.N.); RIKEN Special
Postdoctoral Researchers Program (to Y.K.). Funding
for open access charge: Grants-in-Aid for Scientiﬁc
Research from The Ministry of Education, Culture,
Sports, Science and Technology (22240037 and 22110004
to N.N.).
Conﬂict of interest statement. None declared.
REFERENCES
1. Rabbitts,T.H., Forster,A., Larson,R. and Nathan,P. (1993)
Fusion of the dominant negative transcription regulator CHOP
with a novel gene FUS by translocation t(12;16) in malignant
liposarcoma. Nat. Genet., 4, 175–180.
2. Ichikawa,H., Shimizu,K., Hayashi,Y. and Ohki,M. (1994) An
RNA-binding protein gene, TLS/FUS, is fused to ERG in human
myeloid leukemia with t(16;21) chromosomal translocation.
Cancer Res., 54, 2865–2868.
3. Crozat,A., Aman,P., Mandahl,N. and Ron,D. (1993) Fusion of
CHOP to a novel RNA-binding protein in human myxoid
liposarcoma. Nature, 363, 640–644.
4. Zinszner,H., Albalat,R. and Ron,D. (1994) A novel effector
domain from the RNA-binding protein TLS or EWS is required
for oncogenic transformation by CHOP. Genes Dev., 8,
2513–2526.
5. Doi,H., Okamura,K., Bauer,P.O., Furukawa,Y., Shimizu,H.,
Kurosawa,M., Machida,Y., Miyazaki,H., Mitsui,K., Kuroiwa,Y.
et al. (2008) RNA-binding protein TLS is a major nuclear
aggregate-interacting protein in huntingtin exon 1 with expanded
polyglutamine-expressing cells. J. Biol. Chem., 283, 6489–6500.
6. Woulfe,J., Gray,D.A. and Mackenzie,I.R. (2010)
FUS-immunoreactive intranuclear inclusions in neurodegenerative
disease. Brain Pathol., 20, 589–597.
7. Doi,H., Koyano,S., Suzuki,Y., Nukina,N. and Kuroiwa,Y. (2010)
The RNA-binding protein FUS/TLS is a common
aggregate-interacting protein in polyglutamine diseases.
Neurosci. Res., 66, 131–133.
8. Kwiatkowski,T.J. Jr, Bosco,D.A., Leclerc,A.L., Tamrazian,E.,
Vanderburg,C.R., Russ,C., Davis,A., Gilchrist,J., Kasarskis,E.J.,
Munsat,T. et al. (2009) Mutations in the FUS/TLS gene on
chromosome 16 cause familial amyotrophic lateral sclerosis.
Science, 323, 1205–1208.
9. Vance,C., Rogelj,B., Hortobagyi,T., De Vos,K.J., Nishimura,A.L.,
Sreedharan,J., Hu,X., Smith,B., Ruddy,D., Wright,P. et al. (2009)
Mutations in FUS, an RNA processing protein, cause familial
amyotrophic lateral sclerosis type 6. Science, 323, 1208–1211.
10. Lagier-Tourenne,C., Polymenidou,M. and Cleveland,D.W. (2010)
TDP-43 and FUS/TLS: emerging roles in RNA processing and
neurodegeneration. Hum. Mol. Genet., 19, R46–R64.
11. Lee,B.J., Cansizoglu,A.E., Suel,K.E., Louis,T.H., Zhang,Z. and
Chook,Y.M. (2006) Rules for nuclear localization sequence
recognition by karyopherin beta 2. Cell, 126, 543–558.
12. Neumann,M., Roeber,S., Kretzschmar,H.A., Rademakers,R.,
Baker,M. and Mackenzie,I.R. (2009) Abundant
FUS-immunoreactive pathology in neuronal intermediate ﬁlament
inclusion disease. Acta Neuropathol., 118, 605–616.
13. Neumann,M., Rademakers,R., Roeber,S., Baker,M.,
Kretzschmar,H.A. and Mackenzie,I.R. (2009) A new subtype of
frontotemporal lobar degeneration with FUS pathology. Brain,
132, 2922–2931.
14. Munoz,D.G., Neumann,M., Kusaka,H., Yokota,O., Ishihara,K.,
Terada,S., Kuroda,S. and Mackenzie,I.R. (2009) FUS pathology
in basophilic inclusion body disease. Acta Neuropathol., 118,
617–627.
15. Mackenzie,I.R., Neumann,M., Bigio,E.H., Cairns,N.J.,
Alafuzoff,I., Kril,J., Kovacs,G.G., Ghetti,B., Halliday,G.,
Holm,I.E. et al. (2010) Nomenclature and nosology for
neuropathologic subtypes of frontotemporal lobar degeneration:
an update. Acta Neuropathol., 119, 1–4.
16. Neumann,M., Sampathu,D.M., Kwong,L.K., Truax,A.C.,
Micsenyi,M.C., Chou,T.T., Bruce,J., Schuck,T., Grossman,M.,
Clark,C.M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal
lobar degeneration and amyotrophic lateral sclerosis. Science, 314,
130–133.
17. Sreedharan,J., Blair,I.P., Tripathi,V.B., Hu,X., Vance,C.,
Rogelj,B., Ackerley,S., Durnall,J.C., Williams,K.L., Buratti,E.
et al. (2008) TDP-43 mutations in familial and sporadic
amyotrophic lateral sclerosis. Science, 319, 1668–1672.
18. Kabashi,E., Valdmanis,P.N., Dion,P., Spiegelman,D.,
McConkey,B.J., Vande Velde,C., Bouchard,J.P., Lacomblez,L.,
Pochigaeva,K., Salachas,F. et al. (2008) TARDBP mutations in
individuals with sporadic and familial amyotrophic lateral
sclerosis. Nat. Genet., 40, 572–574.
19. Neumann,M., Mackenzie,I.R., Cairns,N.J., Boyer,P.J.,
Markesbery,W.R., Smith,C.D., Taylor,J.P., Kretzschmar,H.A.,
Kimonis,V.E. and Forman,M.S. (2007) TDP-43 in the ubiquitin
pathology of frontotemporal dementia with VCP gene mutations.
J. Neuropathol. Exp. Neurol., 66, 152–157.
20. Deng,H.X., Zhai,H., Bigio,E.H., Yan,J., Fecto,F., Ajroud,K.,
Mishra,M., Ajroud-Driss,S., Heller,S., Suﬁt,R. et al. (2010)
FUS-immunoreactive inclusions are a common feature in
sporadic and non-SOD1 familial amyotrophic lateral sclerosis.
Ann. Neurol., 67, 739–748.
21. Lerga,A., Hallier,M., Delva,L., Orvain,C., Gallais,I., Marie,J. and
Moreau-Gachelin,F. (2001) Identiﬁcation of an RNA binding
speciﬁcity for the potential splicing factor TLS. J. Biol. Chem.,
276, 6807–6816.
22. Iko,Y., Kodama,T.S., Kasai,N., Oyama,T., Morita,E.H., Muto,T.,
Okumura,M., Fujii,R., Takumi,T., Tate,S. et al. (2004) Domain
architectures and characterization of an RNA-binding protein,
TLS. J. Biol. Chem., 279, 44834–44840.
23. Kuroda,M., Sok,J., Webb,L., Baechtold,H., Urano,F., Yin,Y.,
Chung,P., de Rooij,D.G., Akhmedov,A., Ashley,T. et al. (2000)
Male sterility and enhanced radiation sensitivity in TLS(-/-) mice.
EMBO J., 19, 453–462.
24. Hicks,G.G., Singh,N., Nashabi,A., Mai,S., Bozek,G., Klewes,L.,
Arapovic,D., White,E.K., Koury,M.J., Oltz,E.M. et al. (2000) Fus
deﬁciency in mice results in defective B-lymphocyte development
and activation, high levels of chromosomal instability and
perinatal death. Nat. Genet., 24, 175–179.
25. Fujii,R., Okabe,S., Urushido,T., Inoue,K., Yoshimura,A.,
Tachibana,T., Nishikawa,T., Hicks,G.G. and Takumi,T. (2005)
The RNA binding protein TLS is translocated to dendritic spines
2796 Nucleic Acids Research, 2011,Vol.39, No. 7by mGluR5 activation and regulates spine morphology.
Curr. Biol., 15, 587–593.
26. Ou,S.H., Wu,F., Harrich,D., Garcia-Martinez,L.F. and
Gaynor,R.B. (1995) Cloning and characterization of a novel
cellular protein, TDP-43, that binds to human immunodeﬁciency
virus type 1 TAR DNA sequence motifs. J. Virol., 69, 3584–3596.
27. Buratti,E., Dork,T., Zuccato,E., Pagani,F., Romano,M. and
Baralle,F.E. (2001) Nuclear factor TDP-43 and SR proteins
promote in vitro and in vivo CFTR exon 9 skipping. EMBO J.,
20, 1774–1784.
28. Rabin,S.J., Kim,J.M., Baughn,M., Libby,R.T., Kim,Y.J., Fan,Y.,
La Spada,A., Stone,B. and Ravits,J. (2010) Sporadic ALS has
compartment-speciﬁc aberrant exon splicing and altered
cell-matrix adhesion biology. Hum. Mol. Genet., 19, 313–328.
29. Camats,M., Guil,S., Kokolo,M. and Bach-Elias,M. (2008) P68
RNA helicase (DDX5) alters activity of cis- and trans-acting
factors of the alternative splicing of H-Ras. PLoS ONE, 3, e2926.
30. Hallier,M., Lerga,A., Barnache,S., Tavitian,A. and Moreau-
Gachelin,F. (1998) The transcription factor Spi-1/PU.1 interacts
with the potential splicing factor TLS. J. Biol. Chem., 273,
4838–4842.
31. Yang,L., Embree,L.J., Tsai,S. and Hickstein,D.D. (1998)
Oncoprotein TLS interacts with serine-arginine proteins involved
in RNA splicing. J. Biol. Chem., 273, 27761–27764.
32. Delva,L., Gallais,I., Guillouf,C., Denis,N., Orvain,C. and
Moreau-Gachelin,F. (2004) Multiple functional domains of the
oncoproteins Spi-1/PU.1 and TLS are involved in their opposite
splicing effects in erythroleukemic cells. Oncogene, 23, 4389–4399.
33. Machida,Y., Okada,T., Kurosawa,M., Oyama,F., Ozawa,K. and
Nukina,N. (2006) rAAV-mediated shRNA ameliorated
neuropathology in Huntington disease model mouse.
Biochem. Biophys. Res. Commun., 343, 190–197.
34. Carninci,P., Kasukawa,T., Katayama,S., Gough,J., Frith,M.C.,
Maeda,N., Oyama,R., Ravasi,T., Lenhard,B., Wells,C. et al.
(2005) The transcriptional landscape of the mammalian genome.
Science, 309, 1559–1563.
35. Kino,Y., Washizu,C., Oma,Y., Onishi,H., Nezu,Y., Sasagawa,N.,
Nukina,N. and Ishiura,S. (2009) MBNL and CELF proteins
regulate alternative splicing of the skeletal muscle chloride
channel CLCN1. Nucleic Acids Res., 37, 6477–6490.
36. la Cour,T., Kiemer,L., Molgaard,A., Gupta,R., Skriver,K. and
Brunak,S. (2004) Analysis and prediction of leucine-rich nuclear
export signals. Protein Eng. Des. Sel., 17, 527–536.
37. Cansizoglu,A.E., Lee,B.J., Zhang,Z.C., Fontoura,B.M. and
Chook,Y.M. (2007) Structure-based design of a pathway-speciﬁc
nuclear import inhibitor. Nat. Struct. Mol. Biol., 14, 452–454.
38. Kosugi,S., Hasebe,M., Entani,T., Takayama,S., Tomita,M. and
Yanagawa,H. (2008) Design of peptide inhibitors for the importin
alpha/beta nuclear import pathway by activity-based proﬁling.
Chem. Biol., 15, 940–949.
39. Andersson,M.K., Stahlberg,A., Arvidsson,Y., Olofsson,A.,
Semb,H., Stenman,G., Nilsson,O. and Aman,P. (2008) The
multifunctional FUS, EWS and TAF15 proto-oncoproteins show
cell type-speciﬁc expression patterns and involvement in cell
spreading and stress response. BMC Cell Biol., 9, 37.
40. Anderson,P. and Kedersha,N. (2008) Stress granules: the Tao of
RNA triage. Trends Biochem. Sci., 33, 141–150.
41. Kedersha,N., Chen,S., Gilks,N., Li,W., Miller,I.J., Stahl,J. and
Anderson,P. (2002) Evidence that ternary complex
(eIF2-GTP-tRNA(i)(Met))-deﬁcient preinitiation complexes are
core constituents of mammalian stress granules. Mol. Biol. Cell,
13, 195–210.
42. Dang,Y., Kedersha,N., Low,W.K., Romo,D., Gorospe,M.,
Kaufman,R., Anderson,P. and Liu,J.O. (2006) Eukaryotic
initiation factor 2alpha-independent pathway of stress granule
induction by the natural product pateamine A. J. Biol. Chem.,
281, 32870–32878.
43. Kedersha,N., Cho,M.R., Li,W., Yacono,P.W., Chen,S., Gilks,N.,
Golan,D.E. and Anderson,P. (2000) Dynamic shuttling of TIA-1
accompanies the recruitment of mRNA to mammalian stress
granules. J. Cell Biol., 151, 1257–1268.
44. Eulalio,A., Behm-Ansmant,I. and Izaurralde,E. (2007) P bodies:
at the crossroads of post-transcriptional pathways. Nat. Rev. Mol.
Cell Biol., 8, 9–22.
45. Zhou,F.F., Xue,Y., Chen,G.L. and Yao,X. (2004) GPS: a novel
group-based phosphorylation predicting and scoring method.
Biochem. Biophys. Res. Commun., 325, 1443–1448.
46. Zinszner,H., Immanuel,D., Yin,Y., Liang,F.X. and Ron,D. (1997)
A topogenic role for the oncogenic N-terminus of TLS: nucleolar
localization when transcription is inhibited. Oncogene, 14,
451–461.
47. Gregory,R.I., Yan,K.P., Amuthan,G., Chendrimada,T.,
Doratotaj,B., Cooch,N. and Shiekhattar,R. (2004) The
microprocessor complex mediates the genesis of microRNAs.
Nature, 432, 235–240.
48. Shiohama,A., Sasaki,T., Noda,S., Minoshima,S. and Shimizu,N.
(2007) Nucleolar localization of DGCR8 and identiﬁcation of
eleven DGCR8-associated proteins. Exp. Cell Res., 313,
4196–4207.
49. Wang,X., Arai,S., Song,X., Reichart,D., Du,K., Pascual,G.,
Tempst,P., Rosenfeld,M.G., Glass,C.K. and Kurokawa,R. (2008)
Induced ncRNAs allosterically modify RNA-binding proteins in
cis to inhibit transcription. Nature, 454, 126–130.
50. Perrotti,D., Bonatti,S., Trotta,R., Martinez,R., Skorski,T.,
Salomoni,P., Grassilli,E., Lozzo,R.V., Cooper,D.R. and
Calabretta,B. (1998) TLS/FUS, a pro-oncogene involved in
multiple chromosomal translocations, is a novel regulator of
BCR/ABL-mediated leukemogenesis. EMBO J., 17, 4442–4455.
51. Perrotti,D., Iervolino,A., Cesi,V., Cirinna,M., Lombardini,S.,
Grassilli,E., Bonatti,S., Claudio,P.P. and Calabretta,B. (2000)
BCR-ABL prevents c-jun-mediated and proteasome-dependent
FUS (TLS) proteolysis through a protein kinase
CbetaII-dependent pathway. Mol. Cell. Biol., 20, 6159–6169.
52. Klint,P., Hellman,U., Wernstedt,C., Aman,P., Ron,D. and
Claesson-Welsh,L. (2004) Translocated in liposarcoma (TLS) is a
substrate for ﬁbroblast growth factor receptor-1. Cell Signal, 16,
515–520.
53. Gardiner,M., Toth,R., Vandermoere,F., Morrice,N.A. and
Rouse,J. (2008) Identiﬁcation and characterization of FUS/TLS
as a new target of ATM. Biochem. J., 415, 297–307.
54. Oh,S.M., Liu,Z., Okada,M., Jang,S.W., Liu,X., Chan,C.B.,
Luo,H. and Ye,K. (2010) Ebp1 sumoylation, regulated by TLS/
FUS E3 ligase, is required for its anti-proliferative activity.
Oncogene, 29, 1017–1030.
55. Rappsilber,J., Friesen,W.J., Paushkin,S., Dreyfuss,G. and
Mann,M. (2003) Detection of arginine dimethylated peptides by
parallel precursor ion scanning mass spectrometry in positive ion
mode. Anal. Chem., 75, 3107–3114.
56. Araya,N., Hiraga,H., Kako,K., Arao,Y., Kato,S. and
Fukamizu,A. (2005) Transcriptional down-regulation
through nuclear exclusion of EWS methylated by PRMT1.
Biochem. Biophys. Res. Commun., 329, 653–660.
57. Serman,A., Le Roy,F., Aigueperse,C., Kress,M., Dautry,F. and
Weil,D. (2007) GW body disassembly triggered by siRNAs
independently of their silencing activity. Nucleic Acids Res., 35,
4715–4727.
58. Fujita,K., Ito,H., Nakano,S., Kinoshita,Y., Wate,R. and
Kusaka,H. (2008) Immunohistochemical identiﬁcation of
messenger RNA-related proteins in basophilic inclusions of
adult-onset atypical motor neuron disease. Acta Neuropathol.,
116, 439–445.
59. Kedersha,N., Stoecklin,G., Ayodele,M., Yacono,P.,
Lykke-Andersen,J., Fritzler,M.J., Scheuner,D., Kaufman,R.J.,
Golan,D.E. and Anderson,P. (2005) Stress granules and
processing bodies are dynamically linked sites of mRNP
remodeling. J. Cell Biol., 169, 871–884.
60. Kanai,Y., Dohmae,N. and Hirokawa,N. (2004) Kinesin transports
RNA: isolation and characterization of an RNA-transporting
granule. Neuron, 43, 513–525.
61. Fujii,R. and Takumi,T. (2005) TLS facilitates transport of
mRNA encoding an actin-stabilizing protein to dendritic spines.
J. Cell Sci., 118, 5755–5765.
62. Yoshimura,A., Fujii,R., Watanabe,Y., Okabe,S., Fukui,K. and
Takumi,T. (2006) Myosin-Va facilitates the accumulation of
mRNA/protein complex in dendritic spines. Curr. Biol., 16,
2345–2351.
63. Dormann,D., Rodde,R., Edbauer,D., Bentmann,E., Fischer,I.,
Hruscha,A., Than,M.E., Mackenzie,I.R., Capell,A., Schmid,B.
Nucleic Acids Research,2011, Vol.39, No. 7 2797et al. (2010) ALS-associated fused in sarcoma (FUS) mutations
disrupt Transportin-mediated nuclear import. EMBO J., 29,
2841–2857.
64. Mazroui,R., Huot,M.E., Tremblay,S., Filion,C., Labelle,Y. and
Khandjian,E.W. (2002) Trapping of messenger RNA by
Fragile X Mental Retardation protein into cytoplasmic
granules induces translation repression. Hum. Mol. Genet., 11,
3007–3017.
65. Hua,Y. and Zhou,J. (2004) Survival motor neuron protein
facilitates assembly of stress granules. FEBS Lett., 572, 69–74.
66. Ogawa,F., Kasai,M. and Akiyama,T. (2005) A functional link
between Disrupted-In-Schizophrenia 1 and the eukaryotic
translation initiation factor 3. Biochem. Biophys. Res. Commun.,
338, 771–776.
67. Furukawa,Y., Kaneko,K., Matsumoto,G., Kurosawa,M. and
Nukina,N. (2009) Cross-seeding ﬁbrillation of Q/N-rich
proteins offers new pathomechanism of polyglutamine diseases.
J. Neurosci., 29, 5153–5162.
68. Lu,L., Wang,S., Zheng,L., Li,X., Suswam,E.A., Zhang,X.,
Wheeler,C.G., Nabors,L.B., Filippova,N. and King,P.H. (2009)
Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu
antigen R (HuR) and TIA-1-related protein (TIAR): implications
for impaired post-transcriptional regulation of vascular
endothelial growth factor. J. Biol. Chem., 284, 33989–33998.
69. Emara,M.M., Ivanov,P., Hickman,T., Dawra,N., Tisdale,S.,
Kedersha,N., Hu,G.F. and Anderson,P. (2010)
Angiogenin-induced tRNA-derived stress-induced RNAs promote
stress-induced stress granule assembly. J. Biol. Chem., 285,
10959–10968.
2798 Nucleic Acids Research, 2011,Vol.39, No. 7